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ABSTRACT 
The objectives of this study were to evaluate the risk of neuropathy in patients with Parkinson's 
disease (PD) and to evaluate the role of levodopa exposure as a potential risk factor. A multicenter 
study of 330 patients with PD and 137 healthy controls with a comparable age distribution was 
performed. With respect to levodopa exposure, 144 patients had long exposure (≥3 years) to 
levodopa (LELD), 103 patients had short exposure (<3 years) to levodopa (SELD), and 83 patients 
had no exposure to levodopa (NOLD). Nerve function was evaluated using the reduced total 
neuropathy score. Right sural sensory antidromic and peroneal motor nerve conduction studies 
were performed by neurophysiologists who were blinded to the existence of neuropathy clinical 
features or PD treatment. Overall, 19.40% of patients in the LELD group, 6.80% in the SELD 
group, 4.82% in the NOLD group, and 8.76% in the control group were diagnosed with neuropathy 
(axonal, predominantly sensory). Multivariate logistic analysis indicated that the risk of neuropathy 
was not influenced by disease duration, severity, or sex. The risk of neuropathy increased by 
approximately 8% for each year of age (P < 0.001; odds ratio [OR], 1.08; 95% confidence interval 
[CI], 1.037-1.128). The risk of neuropathy was 2.38 higher in the LELD group than in the control 
group (P = 0.022; OR, 2.38; 95% CI, 1.130-5.014). In a comparison between patients with and 
without neuropathy (Student's ttest), the levodopa dose was higher (P < 0.0001), serum vitamin B12 
levels were lower (P = 0.0102), and homocysteine levels were higher (P < 0.001) in the patients 
with neuropathy. Our results demonstrate that the duration of exposure to levodopa, along with 
age, is the main risk factor for the development of neuropathy. Screening for homocysteine and 
vitamin B12 levels and clinical-neurophysiological monitoring for neuropathy may be advisable in 
patients with PD who are receiving treatment with levodopa. 
 
Parkinson's disease (PD) is a common neurodegenerative disorder that can cause significant 
disability and decreases quality of life. The cardinal physical signs of the disease are distal resting 
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tremor, rigidity, bradykinesia, and asymmetric onset. However, mostly in the later stages of the 
disease, postural instability, muscular cramps, and numbness—more prominent in feet and distal 
legs—also can occur. These latter symptoms also are distinctive of a distal, predominantly sensory 
neuropathy. This overlap between different clinical entities may explain why for many years 
neurologists might have overlooked the concurrence of peripheral involvement as a possible 
additional cause of motor performance and quality-of-life worsening in patients with PD. Only in 
recent years have some studies systematically assessed the presence of neuropathy in PD 
populations,[1-3] suggesting that patients with idiopathic PD frequently may present clinical and/or 
neurophysiological features of polyneuropathy. 
However, some important questions remain open. In particular, mainly due to some methodological 
limitations, like studies that analyzed only case series,[1] single-center studies,[2, 3] and studies that 
lacked or included only small groups of patients with PD who had no levodopa (L-dopa) exposure 
in the study design,[1-3] previous studies were unable to reach a definitive conclusion on the causes 
responsible for the neuropathy. To ascertain the risk factors for neuropathy in idiopathic PD, and 
particularly whether L-dopa plays a crucial, causative role, we carried out a multicenter 
clinical/neurophysiological study in a large sample of patients with PD and age-matched controls, 
stratifying our PD population on the basis of the duration of L-dopa exposure. 
 
Patients and Methods 
Between January and November 2011, we conducted a cross-sectional study involving six Italian 
tertiary referral centers for PD (Cagliari, Genoa, Naples, Pisa, Turin, and Viareggio) by enrolling 
consecutive patients who met inclusion criteria for the study. This study received approval from the 
ethical committees of each center. A written informed consent form was obtained from each patient. 
Patients 
All patients fulfilled United Kingdom Brain Bank criteria for the clinical diagnosis of PD, and the 
diagnosis was determined by movement disorders specialists. We excluded patients from this study 
who had a history of other systemic illnesses, such as chronic infectious diseases, diabetes, or other 
metabolic, endocrine, or autoimmune illnesses; cancer; chronic alcohol consumption; toxic 
exposure, and any family history of neuropathy. The daily dose and duration of L-dopa and 
dopamine agonists were determined for each patient by a retrospective chart review. We defined the 
daily L-dopa dose as the average daily dosage of L-dopa in the last 6 months. With respect to L-dopa 
exposure, patients were subdivided into those with exposure for more than three years (long 
exposure to L-dopa [LELD]), exposure for less than three years (short exposure to L-dopa [SELD]), 
or no exposure (no L-dopa [NOLD]). The criterion for defining SELD as a period no longer than 
three years was arbitrary; however, it was driven by the fact that, after three or four years of L-dopa, 
up to 50% of PD patients can develop dyskinesias and motor fluctuations[4]; this effect is the 
clinical reflection of a breakdown of a neuronal homeostasis in the central nervous system. 
Moreover, although the objective of our research was to explore the peripheral nervous system, we 
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decided to tighten the window of L-dopa exposure to this period. Assessment using the motor 
subscale (part III) from the Unified Parkinson's Disease Rating Scale (UPDRS III) and a complete 
neurological examination were carried out in all patients. No patients were taking any vitamin 
supplementation. 
Controls were mainly recruited from the familial/social network of the patients and had no history 
of neurodegenerative disease or other illness that putatively affects peripheral nerves. Age 
distribution for the control group was comparable to that for the PD group. 
Procedures 
Nerve function was evaluated using a sensitive, validated neuropathy composite score, the reduced 
version of the total neuropathy score (TNSr), which is the version previously validated by 
Cornblath et al[5] and modified by Cavaletti et al.[6] (ie, evaluation of sensory symptoms, pin 
sensibility, vibration sensibility, strength, and deep tendon reflex, without the quantitative 
determination of vibration threshold but with the neurophysiological investigation of sensory sural 
and motor peroneal peripheral nerves). For each patient and control participant, a detailed 
neurological history (with particular reference to the presence of signs of peripheral nerve damage) 
was drawn up. 
As required for TNS design, the presence of sensory, motor, or autonomic symptoms was first 
assessed by interviewing the patients. The neurological examination was based on the standard 
evaluation of strength, deep tendon reflexes, and examination of pin sensibility using a sterile 
disposable needle; and disturbance of vibration sensibility was demonstrated by decreased 
perception of the 128-Hz diapason vibration, as described by Cavaletti et al.[6] 
Nerve conduction studies were performed using standard laboratory techniques. Right sural sensory 
antidromic and peroneal motor nerve conduction was studied using standardized techniques and 
fixed distances. The temperature was maintained at >32°C. To avoid any bias, the clinical 
neurophysiologist was blinded to the participant's condition (ie, exposure to L-dopa or drug dosages 
of PD patients, existence of clinical features of neuropathy). 
To calculate the TNSr, the amplitude of the antidromic sensory potential in one sural nerve and the 
compound muscle action potential (CMAP) in the ipsilateral common peroneal nerve were used. 
The neurophysiological normal reference values necessary for TNS calculation were previously 
determined in each neurological department in age-matched individuals. According to the results 
from the clinical and neurophysiological examinations, the TNSr score was calculated as previously 
described.[5] For each item, the possible score ranged from 0 (normal) to 4 (worst possible results), 
so that the score ranged from 0 to 28. 
According to previously published criteria,[7] only patients who presented a combination of 
neuropathic symptoms or signs with at least an abnormal parameter in one of the explored nerves 
were considered as patients with neuropathy. We determined serum vitamin B12 and homocysteine 
(Hcy) levels for all patients involved in the study. Fasting blood tests were carried out 12 hours after 
the last dose of L-dopa. For those with neuropathy, we performed further blood investigations, 
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including complete blood count, urea, creatinine, liver enzymes, liver function tests, glucose and 
hemoglobin A1C (HbA1C), electrolytes, thyroid function (free tri-iodothyronine, free 
tetraiodothyronine, thyroid-stimulating hormone), erythrocyte sedimentation rate, polymerase chain 
reaction, antinuclear antibody, extracted nuclear antibody testing, rheumatoid factor, and serum 
protein electrophoresis. 
 
Statistical Analysis 
An initial multivariate logistic analysis was used to demonstrate the possible effects on neuropathy 
occurrence of L-dopa exposure, age, sex, disease duration, disease severity, and blood levels of 
vitamin B12 and Hcy. The analysis was carried out considering neuropathy as a dependent variable 
and considering duration of L-dopa exposure, global UPDRS III score (categorical variable), sex, 
age (continuous variable), and their second-order interactions as independent variables. Disease 
duration and levels of vitamin B12 and Hcy (independent continuous variables) were considered 
without interactions. 
On the basis of the results, a second logistic analysis was performed that included only patients with 
PD to demonstrate the possible independent effects of age on neuropathy (considered as a 
confounding variable) and L-dopa exposure (LELD vs SELD and NOLD). A multivariate logistic 
analysis was performed using a backward stepwise procedure based on eliminating the least 
significant interaction and independent variables at each step. The Student t test for the comparison 
of two means was used to evaluate differences in serum vitamin B12 and Hcy levels, TNSr score, 
sensory action potential amplitude of the sural nerve, CMAP amplitude of the peroneal nerve, and 
L-dopa daily dose between patients with and without neuropathy. 
The eventual difference in the pull test score (UPDRS III, sub-item 30) between patients with and 
without neuropathy was evaluated with the z test for difference between two proportions. 
A P value < 0.05 was considered significant. Data from the survey were analyzed using the 
Statistical Package for the Social Sciences (version 19; SPSS Inc., Chicago, IL, USA). 
 
Results 
Between January and November 2011, 472 participants (335 patients with PD and 137 age-matched 
controls) were consecutively screened. Four patients were subsequently excluded because 
hematological findings disclosed previously unrecognized diabetes (high glucose or HbA1C levels 
in three patients) or monoclonal gammopathy (one patient); another patient was excluded because 
as he was diagnosed with cancer after the screening visit. 
Of the patients with PD who were finally included, 144 patients (56 women) had L-dopa exposure 
longer than 3 years (LELD; mean age, 69.1 years; mean illness duration, 9.9 years; mean UPDRS 
III score, 24.1); 103 patients (38 women) had L-dopa exposure shorter than 3 years (SELD; mean 
age, 67.6 years; mean illness duration, 3.8 years; mean UPDRS III score, 18.2); and 83 patients (34 
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women) had no exposure to L-dopa (NOLD; mean age, 62.0 years; mean illness duration, 3.0 years; 
mean UPDRS III score, 15.7). There were 137 controls (70 women; mean age, 68.0 years). 
Twenty-eight of 144 patients (19.40%) with LELD, seven of 103 patients (6.80%) with SELD, four 
of 83 patients (4.82%) with NOLD, and 12 of 137 age-matched controls (8.76%) were diagnosed 
with neuropathy (see Tables 1 and 2). The TNSr score was significantly higher in patients with 
neuropathy than in those without neuropathy (difference in absolute value, 9.8; P < 0.0001; 95% 
confidence interval [CI], 8.9–10.7); the amplitude of the sensory potential of the sural nerve (RV) 
was significantly lower in patients with neuropathy than in those without neuropathy (difference in 
absolute value, 9.0; P < 0.0001; 95% CI, 8.22-9.88). Also, the CMAP of the common peroneal 
nerve (mV) was significantly lower in patients with neuropathy than in those without neuropathy 
(difference in absolute value, 2.6; P < 0.0001; 95% CI, 1.96-3.14). The clinical and 
electrophysiological features of the neuropathic patients were consistent with an axonal, 
predominantly sensory neuropathy. 
 
 
The first multivariate logistic analysis demonstrated that all interactions were not statistically 
significant; therefore, they were eliminated from the model. Moreover, the analysis indicated that 
the risk of neuropathy was not influenced by disease duration (P = 0.91; odds ratio [OR], 1.01), 
disease severity assessed by the UPDRS III total score (P = 0.20; OR, 1.02), sex (P = 0.25; OR, 
1.64), serum vitamin B12 level (P = 0.26; OR, 0.99), or serum Hcy level (P = 0.59; OR, 1.01). 
Consequently, these variables were eliminated from the model. In the end, the risk of neuropathy 
increased by 8% for each year of age (P < 0.001; OR, 1.08; 95% confidence interval [CI], 1.037-
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1.128). Moreover, the risk of neuropathy was 2.38 higher in individuals who had LELD than in 
healthy individuals (P = 0.022; OR, 2.38; 95% CI, 1.130-5.014). The logistic regression model 
(Table 3) clearly indicated that age and LELD were independently associated with neuropathy. 
 
 
The second multivariate logistic analysis (Table 4) unambiguously showed that age and LELD were 
independently associated with neuropathy. Namely, the risk of neuropathy increased by 7% for each 
year of age (P = 0.0055; OR, 1.07; 95% CI, 1.02-1.12). The risk of neuropathy was 3.083 higher in 
individuals who had LELD than in individuals who had short exposure and no exposure to L-dopa 
(P = 0.0035; OR, 3.08; 95% CI, 1.45-6.56). 
 
 
The Student t test indicated that L-dopa dose distribution was significantly higher in patients with 
neuropathy than in those (LELD and SELD) without neuropathy (difference in absolute value, 
404.9; P < 0.0001; 95% CI, 321.5–488.3) (Fig. 1). 
 
 
 
 
Figure 1. The distribution of L-dopa (LD) 
doses (mg/day) in patients who had 
Parkinson's disease (PD) with and without 
neuropathy. 
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The results showed that, among patients with PD who were receiving L-dopa (LELD and SELD) 
and had neuropathy, 22 of 35 had a pull test score ≥2 (UPDRS III, sub-item 30); whereas, among 
those without neuropathy, only 30 of 212 had a pull test score ≥2, equal to 14%. This difference 
was significant (z test; P < 0.0001). 
Serum vitamin B12 levels were significantly lower in patients with neuropathy than in those 
without neuropathy (difference in absolute value, 58.3; P = 0.0008; 95% CI, 24.1–92.4) (Fig. 2). 
Serum Hcy levels were significantly higher in patients with neuropathy than in those without 
neuropathy (difference in absolute value, 4.2; P = 0.0001; 95% CI, 2.03–6.36) (Fig. 3). As stated in 
the study protocol for the patients with PD who had neuropathy, an additional, extensive 
hematological investigation was performed, and the results for all neuropathic patients were within 
normal values. 
 
 
Figure 2. The distribution of serum vitamin B12 levels in patients who had Parkinson's disease 
(PD) with and without neuropathy. 
 
Figure 3. The distribution of homocysteine levels in patients who had Parkinson's disease (PD) 
with and without neuropathy. 
 
Discussion 
In recent years, some studies have reported an increased prevalence of neuropathy in patients with 
PD.[1-3] However, those studies shared an important limitation: they only included patients with 
PD who were exposed to L-dopa. For this reason, although they hypothesized that prolonged L-dopa 
use directly or indirectly leads to neuropathy, they could not exclude the possibility that other 
factors, including PD “alone,” might cause peripheral impairment.[8] With this unanswered issue in 
mind, to ascertain whether L-dopa plays a crucial causative role in neuropathy, we choose to stratify 
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our large PD population according to the duration of L-dopa exposure. Moreover, a group of L-
dopa-naive PD patients also was studied along with a group of healthy controls. 
Our findings provide clear evidence that the duration of L-dopa exposure, but not disease duration 
or disease severity, is strongly associated with the presence of neuropathy in patients with PD, thus 
supporting the role of L-dopa as a main risk factor. In addition, a positive relationship between 
the L-dopa daily dose and the presence of neuropathy has been suggested; that is, the longer the 
duration ofL-dopa treatment and, presumably, the higher the L-dopa dose, the greater the risk of 
neuropathy. 
The positive association of neuropathy with both vitamin B12 deficiency and increased Hcy levels 
observed in our study replicates on a larger scale the data previously published.[1-3, 9, 10] In 
particular, our findings are confirmatory of the data originally described by Rajabally and Martey, 
who reported for the first time a positive relationship between neuropathy and low vitamin B12 
levels,[3] as well as recent data regarding a strong association between neuropathy and increased 
Hcy levels.[1, 2] 
The increase in Hcy during oral L-dopa as well as duodopa intestinal infusion[11-14] are related to 
the consumption of methyl groups by COMT; vitamin B12, vitamin B6, and folate are needed 
cofactors for Hcy metabolism. Vitamin B12 deficiency, which recently was identified as a potential 
cause of reversible peripheral neuropathy in the elderly,[15, 16] reportedly is inversely associated 
with L-dopa dose in patients who have PD and neuropathy. In most cases, as observed in our study, 
vitamin B12 levels were significantly lower than those observed in healthy controls, yet they were 
not always absolutely deficient. This suggests that the neuropathic changes could be related to the 
exposure to toxic metabolites (Hcy, methylmalonic acid [MMA]) resulting from a combination of 
high L-dopa concentration and cobalamine functional insufficiency, rather than vitamin B12 
deficiency per se. 
The increased L-dopa-related Hcy levels and their direct association with the risk of neuropathy 
observed in our cohort confirm the potential toxic effects of this metabolite on peripheral nerves. 
Unfortunately, as a limitation of our study, we could not assess the MMA levels in our patients. 
Hcy can cause neurotoxicity through several mechanisms, by increasing vulnerability to 
mitochondrial toxins and rising free radicals, by inducing inflammatory reactions, and also by 
impairing DNA repair mechanisms.[17-19] L-Dopa-associated, increased Hcy levels reportedly 
were associated with signs of sural axonal neurodegeneration in an electrophysiological study of 
patients with PD and healthy controls.[20] The role of high levels of Hcy in inducing peripheral 
nerve damage has been confirmed in diabetic peripheral neuropathy,[21] in patients with 5,10-
methylenetetrahydrofolate reductase deficiency,[22] and in a recent longitudinal clinical and 
electrophysiological study conducted on a large group of elderly individuals.[23] The evidence that 
only a proportion of PD patients on L-dopa therapy develop neuropathy could be due to a genetic 
susceptibility, for example involving methyltetrahydrofolate reductase, for which the potential risk 
might be related to the possibility of having Hcy elevation with L-dopa therapy.[1] 
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Because the inhibitors of catechol-O-methyltransferase (COMT) can effectively reduce plasma Hcy 
levels,[24] in the present study, we did not plan to recruit patients on stable therapy with COMT 
inhibitors; however, our study's next steps will include the assessment of the putative protective role 
of COMT inhibition on the development of neuropathy and the clinical and electrophysiological 
follow-up of PD patients with neuropathy after adequate supplementation therapy. 
We decided to assess neuropathy by means of both clinical and electrophysiological measures using 
a blinded procedure; however, blinding is extremely difficult in this setting and, for obvious 
reasons, only neurophysiologists, but not neurologists, were blinded to the existence of clinical 
features of neuropathy or disease treatment (exposure and time of exposure to L-dopa or drug doses 
in patients with PD). In previous reports, either investigators were not blinded with regard to the 
patient's condition[1,2] or the unblinded assessment was carried out only on a clinical 
basis.[3] Because we were aware that the diagnosis of peripheral neuropathy based only on clinical 
grounds might be difficult because of the wide overlapping of PD-related symptoms and 
neuropathy-related complaints (pain, paraesthesias, sensory symptoms, and impaired balance), we 
defined patients and controls as neuropathic when there was an abnormal electrophysiological 
parameter in at least one of the explored nerves, but the diagnosis had to be confirmed on clinical 
grounds. In all neuropathic patients, we observed a reduction of sural nerve amplitude, which was 
proportionally more relevant than the common peroneal CMAP reduction. Similarly, the 
impairment of the sensory item on the rTNS was greater than that of the motor item (which was 
normal or only slightly abnormal in the large majority of the neuropathic patients). Taken together, 
the clinical and electrophysiological features of the neuropathic patients were consistent with a 
predominantly sensory neuropathy. On the other hand, we are aware that the criteria chosen for the 
diagnosis of neuropathy in the present study were selective, and both asymptomatic and small fiber 
neuropathies could have been under diagnosed (the former lacking the criteria for neuropathy-
related complaints, and the latter lacking the electrophysiological criteria). 
In summary, we observed a significantly greater prevalence of neuropathy in patients with PD 
compared with healthy controls, and there was a significant relationship of time and, to a lesser 
extent, dose exposure to L-dopa. To date, the clinical relevance of sensory neuropathy in the context 
of PD motor disability had not been previously assessed. Our findings of an association between 
neuropathy and postural instability might highlight the effect of peripheral involvement in 
worsening PD motor impairment. Because the postural imbalance due to neuropathy-related sensory 
disturbances can be treated by specific rehabilitative protocols, which may differ from those 
classically adopted for PD, the early detection and management of neuropathy in the course of PD 
might have great clinical relevance. 
The positive association between neuropathy, low serum vitamin B12 levels, and mainly high 
serum Hcy levels could be related to L-dopa exposure (in terms of duration and, presumably, daily 
amount) in predisposed individuals. Periodic Hcy, vitamin B12, and folate screening, together with 
serial clinical and neurophysiological assessment for neuropathy, may be advisable in patients with 
PD who are receiving L-dopa treatment. We cannot exclude the possibility that the lack of other 
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detoxificant factors, such as vitamin B6 either alone or in combination with vitamin B12 deficiency, 
as recently described in two cases of PD with axonal neuropathy in patients receiving duodopa 
treatment,[9] could play a role in altering peripheral nerve homeostasis. However, the dietary 
supplementation of vitamin B6 is not advisable in patients with PD because of the potential 
interference with L-dopa metabolism. 
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